Indication
Refractory Malignant Brain Neoplasm
1 clinical trial
2 products
1 drug
Clinical trial
Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain TumorsStatus: Recruiting, Estimated PCD: 2024-08-24
Drug
cyclophosphamideProduct
Fludarabine